SCHEMBL4334230

SCHEMBL4334230

Brc1ccccc1SCc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.61
MAOA P21397 2/20 0.48
MAOB P27338 2/20 0.48
HTR7 P34969 1/20 0.48
HSD17B10 Q99714 1/20 0.45
KMT2A Q03164 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
PTPRC P08575 1/20 0.43
CA12 O43570 4/20 0.42
CA1 P00915 4/20 0.42
CA2 P00918 4/20 0.42
CA9 Q16790 3/20 0.42
CA14 Q9ULX7 1/20 0.42
LMNA P02545 1/20 0.42
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HTT P42858 1/20 0.40
CA7 P43166 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14328043 0.84 POLB (0.48) POLBMAOAMAOBHTR7KMT2A
SCHEMBL30484939 0.83 POLB (0.52) POLBHSD17B10KMT2AL3MBTL1PTPRC
SCHEMBL1118636 0.83 POLB (0.52) POLBHSD17B10KMT2AL3MBTL1PTPRC
SCHEMBL1118653 0.83 POLB (0.52) POLBMAOAMAOBHTR7HSD17B10
SCHEMBL30231962 0.83 POLB (0.52) POLBMAOAMAOBHTR7HSD17B10
SCHEMBL16936699 0.80 POLB (0.49) POLBMAOAMAOBHSD17B10KMT2A
SCHEMBL31011604 0.80 APP (0.49) MAOAMAOBHTR7KMT2ACA12
SCHEMBL30231940 0.80 POLB (0.49) POLBMAOAMAOBHTR7HSD17B10
SCHEMBL1118487 0.80 POLB (0.49) POLBMAOAMAOBHTR7HSD17B10
SCHEMBL1770589 0.79 POLB (0.47) POLBMAOAMAOBHSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129828-A1 S1P1 RECEPTOR AGONISTS AND USE THEREOF AMGEN INC. 2012-05-24 US disclosed
WO-2009154780-A1 S1P1 RECEPTOR AGONISTS AND USE THEREOF AMGEN INC. (US) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129828-A1 S1P1 RECEPTOR AGONISTS AND USE THEREOF S1PR1, S1PR5, S1PR2 POLB 4255/4885MAOA 3349/4885MAOB 3108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.